Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS).

Full DD Report for MRNS

You must become a subscriber to view this report.


Recent News from (NASDAQ: MRNS)

Marinus Has A Long And Difficult Road Ahead In Postpartum Depression
Note: This article, edited for public distribution, was first provided to members of my exclusive marketplace on December 11th, when shares of Marinus (MRNS) were trading at ~$5.20. Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic dif...
Source: SeekingAlpha
Date: December, 15 2018 01:44
Healthcare and M&A stocks up in premarket trade
Nutrisystem (NASDAQ: NTRI ) +31%  on cash and stock offer from Tivity Health. More news on: Nutrisystem Inc, Mitek Systems Inc., Axsome Therapeutics, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: December, 10 2018 09:11
Marinus Pharma's ganaxolone shows positive action in mid-stage postpartum depression studies; shares up 35% premarket
Marinus Pharmaceuticals (NASDAQ: MRNS ) is up  35%  premarket on average volume in reaction to its announcement of positive results from Phase 2 studies evaluating intravenously administered ganaxolone in women with postpartum depression (PPD). More news on: Marinus Pharmaceuti...
Source: SeekingAlpha
Date: December, 10 2018 08:10
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
Ganaxolone was safe and well-tolerated Ganaxolone IV demonstrated fast-acting, robust and durable efficacy Interim data with ganaxolone oral supports IV to oral administration Conference call to be held today at 8:30 AM ET RADNOR, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Mar...
Source: GlobeNewswire
Date: December, 10 2018 07:30
Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oil States International, Inc. (NYSE:OIS), Brightcove Inc. (NASDAQ:BCOV),...
Source: GlobeNewswire
Date: November, 06 2018 07:30
Positive Ad Com vote on Sage's brexanolone in PPD a positive for Marinus Pharma
Friday's thumbs up from an FDA advisory committee on Sage Therapeutics' (NASDAQ: SAGE ) GABA modulator brexanolone for postpartum depression (PPD) could stoke buying in Marinus Pharmaceuticals (NASDAQ: MRNS ). It is also developing a GABA modulator, ganaxolone, for PPD, albeit with a longer ...
Source: SeekingAlpha
Date: November, 05 2018 09:28
Denali Follows Up First-Mover Advantage In LRRK2 With Sanofi Deal To Evaluate RIPK1 Inhibitors
Understanding Denali as an investment I previously explored the over-arching potential of the unique 'transport vehicle' platform perfected by Denali Therapeutics ( DNLI ) for the shuttling of large-molecule therapeutics across the blood-brain-barrier. Since I posted that analysis, the ...
Source: SeekingAlpha
Date: November, 05 2018 08:56
Marinus Pharmaceuticals misses by $0.06
Marinus Pharmaceuticals (NASDAQ: MRNS ): Q3 GAAP EPS of -$0.27 misses by $0.06. More news on: Marinus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 29 2018 07:33
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
RADNOR, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today pr...
Source: GlobeNewswire
Date: October, 29 2018 07:30
Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
RADNOR, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou,...
Source: GlobeNewswire
Date: October, 10 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-173.533.453.583.06031,816,033
2018-12-143.603.63993.833.591,794,273
2018-12-133.663.6353.92013.378,063,002
2018-12-124.614.194.674.103,642,291
2018-12-115.335.095.334.951,186,624

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-17269,286760,39035.4142Short
2018-12-14195,752822,66223.7949Cover
2018-12-13758,0312,487,03830.4793Cover
2018-12-12639,9391,252,72151.0839Short
2018-12-11153,510439,91134.8957Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MRNS.


About Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

Logo for Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: MRNS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 23 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 07 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: MRNS)

      Daily Technical Chart for (NASDAQ: MRNS)


      Stay tuned for daily updates and more on (NASDAQ: MRNS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: MRNS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MRNS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MRNS and does not buy, sell, or trade any shares of MRNS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/